Vascular effects of nonsteroidal antiinflammatory drugs

被引:24
|
作者
Soubrier, Martin [1 ]
Rosenbaum, David [2 ]
Tatar, Zuzana [1 ]
Lahaye, Clement [1 ]
Dubost, Jean-Jacques [1 ]
Mathieu, Sylvain [1 ]
机构
[1] Hop G Montpied, Serv Rhumatol, F-63003 Clermont Ferrand, France
[2] GHU Pitie Salpetriere, AP HP, Pole Cardiol Endocrinol Nutr, Unite Prevent Malad Cardiovasc, F-75013 Paris, France
关键词
Nonsteroidal antiinflammatory drugs; Aspirin; Acetaminophen; Myocardial infarction; Stroke; Cardiovascular death; RANDOMIZED CONTROLLED-TRIAL; PROTON-PUMP INHIBITOR; MYOCARDIAL-INFARCTION; CARDIOVASCULAR EVENTS; BLOOD-PRESSURE; GASTROINTESTINAL TOXICITY; RHEUMATOID-ARTHRITIS; ULCER COMPLICATIONS; PRIMARY PREVENTION; NATIONWIDE COHORT;
D O I
10.1016/j.jbspin.2012.12.002
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The effect of nonsteroidal antiinflammatory drugs (NSAIDs) on the risk of cardiovascular events remains controversial. Among NSAIDs, only low-dose aspirin exerts protective vascular effects. Low-dose aspirin has been proven effective for secondary prevention. For primary prevention, the usefulness of low-dose aspirin is debated, as illustrated by the differences in recommendations across countries. NSAIDs other than aspirin, whether COX-2 selective or nonselective, increase the risk of cardiovascular events. Among them, naproxen is associated with the smallest risk increase. In patients with a history of coronary artery disease, diclofenac seems to carry the greatest risk, but all NSAIDs should be avoided. Uncertainties persist about aspirin interactions with other NSAIDs and with proton pump inhibitors. An adverse effect of acetaminophen on the risk of cardiovascular disease cannot be completely ruled out. (C) 2013 Societe francaise de rhumatologie. Published by Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:358 / 362
页数:5
相关论文
共 50 条